Onglyza for type-2 diabetes gets approval
The FDA has given approval for Onglyza. The drug is used to treat type-2 diabetes. The drug has to be taken in a daily basis in combination with diet and exercise.
The Onglyza is made by Bristol-Myers Squibb and distributed by Bristol-Myers Squibb and AstraZeneca Pharmaceuticals. It was tested in diabetic patients who are relatively at low risk of heart diseases.
The company is yet to identify the effect in high risk patients.
The official name of the drug is saxagliptin. It is a class of type-2 diabetes drugs called DPP-4 inhibitors. The first of its kind was approved by the FDA in 2006.
In another case of approval, a drug called DPP-4 inhibitor, Takeda’s algoliptin was rejected by the FDA last month.
The drug which falls under DPO-4 works in the body by blocking an enzyme that degrades GLP-1 which is a short-lived hormone. It stimulates the insulin release from the pancreas and lowers blood sugar levels.